Efficacy and Safety of Avatrombopag vs. Avatrombopag Combined With rhTPO in the Treatment of SAA

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

Anemia, Aplastic

Interventions

DRUG

Avatrombopag

Avatrombopag was given 40 mg/ time, once a day, orally, for 3 months.

DRUG

Avatrombopag +rhTPO

Avatrombopag: 40 mg/ time, once a day, orally; rhTPO: 15000U/ time, once a day, subcutaneous injection; Both were 3 months.

All Listed Sponsors

collaborator

Fosun Pharmaceutical Distribution Jiangsu co., Limited

UNKNOWN

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER

NCT06254287 - Efficacy and Safety of Avatrombopag vs. Avatrombopag Combined With rhTPO in the Treatment of SAA | Biotech Hunter | Biotech Hunter